Omega-3 Fatty Acids and Brain Health: One Size Does Not Fit All

Background: Cognitive impairment, particularly in the elderly, affects millions of people globally. While many Omega-3 fatty acid (FA) formulations are available in Canada, their benefits for brain health/cognitive function are not well-defined. Objective: To identify the clinical efficacy of Omega-3 FA formulations in improving cognitive function. Methods: We performed PubMed searches for clinical efficacy evidence from randomized controlled trials on Omega-3 FAs and brain/mental/cognitive health. The clinical efficacy of each study was categorized by a 5-point scale: 0 = no effect, 1 = marginal, 2 = mild, 3 = moderate, 4 = prominent (p Results: No studies reported negative cognitive effects in patients. Supplements with Omega-3 showed clinical benefits in 3 categories of patients: mild cognitive impairment (MCI), Alzheimer’s disease (AD), and dementia, with a mean of “moderate effect” for all groups. Omega-3 formulations with a total dose > 1000 mg/day showed higher efficacy in all groups. Efficacy response to Omega-3 supplements correlated with total dose, and to a lesser degree with docosahexaenoic acid (DHA) dose. Omega-3 studies of DHA:EPA (eicosapentaenoic acid) ratios 3:1 and 4:1 showed the highest efficacy versus no effect. Conclusions: Omega-3 formulations with a total daily dose of ≥1000 mg and DHA:EPA ratio of 3:1 and higher are most effective compared to other formulations in improving cognitive function in patients with MCI, AD, and dementia.